At GNS, we reveal the hidden biological circuitry of disease to create the world’s most accurate digital twins. These digital twins are powered by the recent explosive growth of multi-omic and clinical patient data and our patented Causal AI and Simulation technology REFS™.
Gemini Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across “digital twins cohorts” to discover and validate novel drug targets.
Gemini Digital Twins also enable the simulation of disease progression and drug response at the individual patient level across “digital twins cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.
Meet Gemini
Digital Twin
Gemini – Digital Twin is fueled by integrated multi-omic and clinical patient data in specific diseases from a rapidly growing array of world class partners and the patented causal AI and simulation technology, REFS™. These “digital twins” link patient characteristics to drug treatments to the “revealed” complex genetic and molecular mechanisms and pathways driving clinical outcomes, enabling the world’s most accurate simulation of disease progression and drug response at an individual patient level across “digital twins cohorts.” Gemini Digital Twins have been launched in multiple myeloma, prostate cancer, Alzheimer, and Parkinson’s, with several more in development.
Collaborate with GNS to Discover and Develop
Innovative Therapeutics
Gemini Digital Twin
Data Partners
Gemini Digital Twin
Biopharma Partners
